
|Videos|September 1, 2017
- Non-Small Cell Lung Cancer
- Volume 1
- Issue 1
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
Author(s)Lyudmila A. Bazhenova, MD
Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the factors to take into consideration when treating a patient with non-driver non–small cell lung cancer with bevacizumab (Avastin).
Articles in this issue
about 8 years ago
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLCabout 8 years ago
Emerging Treatment Strategies in Nonsquamous NSCLCabout 8 years ago
Nonbiomarker NSCLC Population a Challenging Obstacle, Expert Says



































